Amendment Tool

v1.6 06 December 2021

For office use

QC: No

Short project title*:											
IRAS project ID* (or REC reference if no IRAS project ID is available):	314379										
Sponsor amendment reference number*:	Non-Substantial Am	nmendment Three (NSA03)									
Sponsor amendment date* (enter as DD/MM/YY):	02 March 2023										
Briefly summarise in lay language the main changes proposed in this amendment. Explain the purpose of the changes and their significance for the study. If the amendment significantly alters the research design or methodology, or could otherwise affect the scientific value of the study, supporting scientific information should be given (or enclosed separately). Indicate whether or not additional scientific critique has been obtained (note: this field will adapt to the amount of text entered)*:	Addition of sites to A Hospital and Alexand with PI Manish Chab Ramsaran, Universit PI Jenny Gwynn.	dra Hospital) with F Iani, Liverpool Univ	PI Olivia Kelsall, Uni /ersity Hospitals NH	ted Lincolnshire H	lospitals NHS Tru ust with PI Richar						
				Specific stu	ıdy						
Project type (select):			Research tis	ssue bank							
				Research da	atabase						
Has the study been reviewed by a UKECA-recognised Res Committee (REC) prior to this amendment?:	٢	'es		No							
What type of UKECA-recognised Research Ethics Commit	NHS/HSC REC										
is applicable? (select):				Ministry of D	efence (MoDREC						
Is all or part of this amendment being resubmitted to the R Committee (REC) as a modified amendment (i.e. a subst amendment previously given an unfavourable opinion)?	١	/es	No								
Where is the NHS/HSC Research Ethics Committee (REC) that reviewed	England	Wales	Scotland	Northern Irelan						
the study based?:	,	No	Yes	No	No						
Was the study a clinical trial of an investigational medicinal OR does the amendment make it one?:	I product (CTIMP)	١	No								
Was the study a clinical investigation or other study of a modes the amendment make it one?:		١	'es		No						
Does this clinical investigation or other study of a meo require a Notice of No Objection from MHRA Devices		Yes	No								
Did the study involve the administration of radioactive subs requiring ARSAC review, OR does the amendment introdu	١	′es	No								
Did the study involve the use of research exposures to ion (not involving the administration of radioactive substances) amendment introduce this?:	١	′es	No								
Did the study involve adults lacking capacity OR does the a introduce this?:	amendment	٢	′es		No						
Did the study involve access to confidential patient informa direct care team without consent OR does the amendment		۲	/es	No							
Did the study involve prisoners or young offenders who are supervised by the probation service OR does the amendm this?:		١	′es	No							
Did the study involve children OR does the amendment int	troduce this?:	Υ	′es	No							
Did the study involve NHS/HSC organisations prior to this	amendment?:	٢	'es								
Did the study involve non-NHS/HSC organisations OR doe amendment introduce them?:	es the	١	′es	No							
		England	Wales	Scotland	Northern Irelan						
Lead nation for the study:		Yes	No	No	No						
Which nations had participating NHS/HSC organisations p amendment?	rior to this	Yes	No	No	No						
Which nations will have participating NHS/HSC organisation amendment?	ons after this	Yes	No	No	No						
Was this a "single site, self sponsored" study in England or	14/1 : /										

Section 2: Summary of change(s)

Please note: Each change being made as part of the amendment must be entered separately. For example, if an amendment to a clinical trial of an investigational medicinal product (CTIMP) involves an update to the Investigator's Brochure (IB), affecting the Reference Safety Information (RSI) and so the information documents to be given to participants, these should be entered into the Amendment Tool as three separate changes. A list of all possible changes is available on the "Glossary of Amendment Options" tab. To add another change, click the "Add another change" box.

Change 1										
Area of change (select)*:	Participating Organisa	ations								
Specific change (select - only available when area of change is selected first)*:	Addition of sites unde	rtaking the same a	activities as existing	g sites						
Further information (free text - note that this field will adapt to the amount of text entered):	Addition of sites to Al Hospital and Alexand with PI Manish Chabl Ramsaran, University PI Jenny Gwynn.	ra Hospital) with P ani, Liverpool Univ	l Olivia Kelsall, Uni ersity Hospitals NH	ted Lincolnshire H	ospitals NHS Trust st with PI Richard					
Applicability:		England	Wales	Scotland	Northern Ireland					
Where are the participating NHS/HSC organisations locate by this change?*:	d that will be affected	Yes	No	No	No					
Will all participating NHS/HSC organisations be affected by some? (please note that this answer may affect the categor change):	• •	Ą	All	So	ome					
		Add another change								

Section 3: Declaration(s) and lock for submission

Declaration by the Sponsor or authorised delegate

I confirm that the Sponsor takes responsibility for the completed amendment tool I confirm that I have been formally authorised by the Sponsor to complete the amendment tool on their behalf

Name [first name and surname]*:	Sandra Mulligan
Email address*:	Sandra.mulligan@Uhbw.nhs.uk

Lock for submission

Please note: This button will only become available when all mandatory (*) fields have been completed. When the button is available, clicking it will generate a locked PDF copy of the completed amendment tool which must be included in the amendment submission. Please ensure that the amendment tool is completed correctly before locking it for submission.

Lock for submission

After locking the tool, proceed to submit the amendment online. The "Submission Guidance" tab provides further information about the next steps for the amendment.

Section 4: Review bodies for the amendment

Please note: This section is for information only. Details in this section will complete automatically based on the options selected in Sections 1 and 2.

								F	Review	bodie	s								
		UK wide:					Eng	England and Wales:			Scotland:			Northern Ireland:					
	REC	Competent Authority MHRA - Medicines	Competent Authority MHRA - Devices	ARSAC	Radiation Assurance	UKSW Governance	REC (MCA)	CAG	SHAMH	HRA and HCRW Approval	REC (AWIA)	РВРР	SPS (RAEC)	National coordinating function	HSC REC	HSC Data Guardians	Prisons	National coordinating function	Categor
Change 1:						(Y)		(Y)		(Y)									New site
Overall reviews for the amendr	nent:																		
Full review:						Ν		Ν		Ν									
Notification only:						Y		Y		Y									
Overall amendment type:	No	Non-substantial, no study-wide review required																	
Overall Category:	Ne	ew site																	